Long-term treatment with guselkumab is associated with sustained improvements in joint/skin symptoms and disease activity among patients with active PsA.
Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...
Researchers from Nanjing University and Peking University presented the discovery and preclinical characterization of novel NLRP3 inhibitors as potential therapeutic candidates for the treatment of ...